Replies to post #394844 on Zeev's Turnips Patch-No Politics (ZEEV)

[marginnayan]

EYET update:

CEO on CNBC confidently said that there are 'problems' with the preliminary data that DNA provided and that partnership with PFE is going strong.

------------

Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)
5/24/2005 8:30:28 PM

NEW YORK, May 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Eyetech Pharmaceuticals, Inc. (EYET) announced that it will hold a conference call to reiterate its confidence in Macugen and discuss issues presented by a potential competitor's recently released preliminary, top-line clinical trial data for the potential use of an antibody fragment in the treatment of neovascular age-related macular degeneration (neovascular AMD).Neovascular AMD is the leading cause of blindness in people over 60 years of age.

EYET will hold the conference call and simultaneous webcast on Thursday, May 26, 2005, at 8:30 a.m., Eastern Time

----

One day patience pays off.